Stock Events

Stock Events

OKYO Pharma Limited 

$0.01
12
-$0.01-32.51% Friday 19:39

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
19.39M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

31MarExpected
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
-0
-0
-0
0
Expected EPS
0
Actual EPS
-0.0021

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EMMLF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. competes in the biopharmaceutical sector focusing on ophthalmology among other areas, directly competing with OKYO's eye disease treatments.
Novartis
NVS
Mkt Cap237.61B
Novartis AG, through its ophthalmology division, competes in developing treatments for eye diseases, similar to OKYO Pharma's focus.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie Inc. has a strong presence in the pharmaceuticals market, including treatments for eye conditions that compete with OKYO's product pipeline.
Bausch Health Companies
BHC
Mkt Cap2.62B
Bausch Health Companies Inc., through its eye health products, competes directly with OKYO Pharma in the ophthalmology market.
Regenxbio
RGNX
Mkt Cap645.07M
REGENXBIO Inc. is involved in the development of gene therapies for eye diseases, positioning it as a competitor to OKYO Pharma's eye disease treatments.
Biogen
BIIB
Mkt Cap22.63B
Biogen Inc. has investments in therapies for neurological conditions, some of which include ophthalmologic applications, indirectly competing with OKYO.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. is broadly in the biopharmaceutical field with a focus on viral diseases but its expansion into other areas can position it as a competitor to OKYO.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a diverse pharmaceutical portfolio, including investments in treatments for eye diseases, making it a potential competitor to OKYO Pharma.

About

Financial Conglomerates
Finance
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Show more...
CEO
Dr. Gary S. Jacob Ph.D.
Employees
7
Country
GG
ISIN
GG00BD3FV870
WKN
000A2JQ3D

Listings

XNAS
US
OKYO
BOATS
BOATS
OKYO.BOATS

0 Comments

Share your thoughts

FAQ

What is OKYO Pharma Limited stock price today?▼
The current price of EMMLF is $0.01 USD — it has decreased by -32.51% in the past 24 hours. Watch OKYO Pharma Limited stock price performance more closely on the chart.
What is OKYO Pharma Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange OKYO Pharma Limited stocks are traded under the ticker EMMLF.
What is OKYO Pharma Limited market cap?▼
Today OKYO Pharma Limited has the market capitalization of 19.39M
What were OKYO Pharma Limited earnings last quarter?▼
EMMLF earnings for the last quarter are -0 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
How many employees does OKYO Pharma Limited have?▼
As of April 01, 2026, the company has 7 employees.
In which sector is OKYO Pharma Limited located?▼
OKYO Pharma Limited operates in the Healthcare sector.
When did OKYO Pharma Limited complete a stock split?▼
The last stock split for OKYO Pharma Limited was on May 22, 2023 with a ratio of 1:65.
Where is OKYO Pharma Limited headquartered?▼
OKYO Pharma Limited is headquartered in London, GG.